Creative Touch Permanent Makeup and Aesthetics

Acne vulgaris is the most commonly diagnosed skin condition worldwide, but its framing as primarily an infectious disease of adolescence is wrong on both counts – and getting the framing right has direct consequences for how practitioners sequence treatment, counsel clients, and position interventions. At a mechanistic level, acne is a metabolic-inflammatory disease of the pilosebaceous unit, organised around a single upstream imbalance: when insulin and IGF-1 signalling excludes FoxO1 from the keratinocyte nucleus, mTORC1 activates unchecked, simultaneously driving sebocyte lipogenesis, follicular keratinocyte hyperproliferation, and androgen receptor amplification. The four classic pillars – follicular hyperkeratinisation, seborrhoea, Cutibacterium acnes dysbiosis, immune activation – are co-ordinated downstream outputs of that metabolic shift, not independent causes operating in parallel.

C. acnes is not the enemy. It is a commensal whose follicular community has shifted from diversity-maintaining IB/Type II phylotypes toward inflammatory IA1 dominance in a changed follicular environment. The S/C ratio and phylotype balance are the relevant microbiological variables – not total C. acnes abundance, which shows no significant difference between acne and healthy skin in meta-analysis. Rising adult acne prevalence – up 66.6% between 1990 and 2021 – reflects exposome pressures (urban pollution, dietary industrial transition, circadian disruption) converging on the same FoxO1/mTORC1 axis, none of which involves any change in human genetics. And there is now Mendelian randomisation evidence supporting a causal gut-skin axis contribution, positioning acne as a disease with both local follicular and systemic immune amplification routes.

Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit – the anatomical complex of hair follicle and sebaceous gland embedded in the dermis at sebaceous-dominant skin sites. Every acne lesion, from the smallest comedone to the deepest nodulocystic presentation, originates within or immediately adjacent to that structure. Everything that makes acne what it is – follicular obstruction, sebum overproduction, microbial community shift, immune activation, and ultimately collagen destruction – happens because of what is occurring inside the pilosebaceous unit, and understanding why requires a framework that goes considerably deeper than the traditional four-pillar model.

Acne as a metabolic-inflammatory disease

The most useful conceptual reframe in contemporary acne science is Melnik’s characterisation of acne as “an inflammasomopathy of the sebaceous follicle induced by deviated FoxO1/mTORC1 signalling.” It is not merely a description. It is a disease model – one that positions the four classic pathogenic pillars not as independent causes but as co-ordinated outputs of a single metabolic imbalance occurring upstream. ^[11]

The mechanism is this. Insulin and IGF-1 – elevated by high-glycaemic-load diet, dairy protein intake, and insulin resistance – activate PI3K/Akt signalling in sebaceous and follicular keratinocytes. Akt phosphorylates FoxO1, the transcription factor that, when active in the cell nucleus, suppresses sebocyte proliferation, lipogenesis, androgen receptor expression, and the inflammatory gene programmes that drive acne. Phosphorylated FoxO1 is excluded from the nucleus and can no longer suppress mTORC1. mTORC1, now uninhibited, simultaneously activates three downstream programmes: sebocyte lipogenesis via SREBP-1 and androgen-driven lipid synthesis, follicular keratinocyte hyperproliferation via S6K1-mediated ribosomal biogenesis, and androgen receptor amplification via mTORC1-dependent AR upregulation. ^[11]

The result is the entire acne phenotype from a single upstream event. Excess sebum provides the lipid-rich, anaerobic follicular substrate that selects for inflammatory C. acnes phylotypes. Follicular keratinocyte hyperproliferation produces the microcomedo. Androgen receptor amplification sustains the cycle independently of circulating androgen levels – which is why most adult women with hormonal acne have normal blood androgen tests. The inflammation that follows is not an initiating event; it is the immune system’s response to the already-dysregulated follicular environment.

A 2020 prospective case-control study confirmed that serum FoxO1 protein levels are reduced in acne patients both with and without metabolic syndrome, while mTOR expression is elevated specifically in patients with both acne and metabolic syndrome. The FoxO1/mTORC1 axis sits at the intersection of metabolic and dermatological disease – which is precisely why the treatments that address it most fundamentally (isotretinoin’s RAR/RXR-mediated mTORC1 suppression; dietary glycaemic load reduction; spironolactone’s androgen receptor blockade) produce the most sustained remissions. ^[1]

The exposome – why adult prevalence is rising

Between 1990 and 2021, global adult acne incidence rose by 66.6%. No change in human genetics explains that. The answer lies in environmental pressures converging on the same upstream metabolic pathways. ^[4]

A March 2026 Frontiers in Immunology review explicitly mapped the exposome contribution to acne pathogenesis, identifying three converging routes beyond diet. ^[8]

Urban pollution. Particulate matter (PM2.5) and nitrogen dioxide activate the aryl hydrocarbon receptor (AhR) in follicular keratinocytes – a ligand-activated transcription factor that induces CYP1A1 and drives comedogenesis through a pathway independent of IGF-1 or androgen signalling. A 2025 systematic review of environmental pollution and acne confirmed PM2.5 and NO2 as acne exacerbators via oxidative stress, skin barrier disruption, and microbiome perturbation. AhR is a meaningful addition to the pathogenic model: it means urban residents face a comedogenic stimulus operating in parallel to the dietary/metabolic route, which compounds in populations experiencing both dietary industrial transition and urbanisation simultaneously. ^[12]

Circadian disruption. Disrupted melatonin secretion and elevated nocturnal cortisol – both consequences of artificial light exposure, shift work, and irregular sleep – activate androgen production and reduce the overnight acid mantle restoration that supports commensal C. acnes ecology. Cortisol independently elevates IGF-1, re-entering the FoxO1/mTORC1 loop.

Dietary industrial transition. High-glycaemic-load diets raise insulin, which raises IGF-1, which phosphorylates FoxO1. Dairy proteins – particularly whey – provide a second, independently insulinotropic route to the same mTORC1 activation. A 2025 Mendelian randomisation analysis identified sugar-sweetened beverage consumption as an independently associated causal risk factor. ^[4] The mechanistic chain is well-established; population-level trial evidence for dietary modification in acne shows real but individually variable effects. Diet modulates acne in predisposed individuals via the IGF-1/mTORC1 pathway. It does not cause acne in isolation, and dietary change alone is rarely sufficient treatment.

The exposome framing matters clinically because it positions acne as a disease that is environmentally amplified in populations over decades – not a condition that individuals simply develop or don’t develop based on genetics and adolescent hormones. A client presenting with adult acne in an urban environment, working irregular hours, eating a typical Western diet, is carrying a meaningful cumulative exposome burden on top of whatever underlying predisposition they have. That complexity doesn’t simplify the treatment approach, but it does change the conversation.

C. acnes – dysbiosis, not infection

The correct framing here is important enough to state without hedging. A meta-analysis of 18 studies comprising 102 healthy controls and 401 acne samples found no statistically significant difference in total C. acnes abundance between acne-affected and healthy skin. What differed was the Staphylococcus/C. acnes ratio (S/C ratio), the distribution of C. acnes phylotypes within the community, and microbial diversity. Acne is a community composition problem. Not an overgrowth problem. ^[3]

The phylotype architecture matters:

Phylotype IA1 (pathogenic-associated): enriched 48.3% among infection isolates, with an odds ratio of 1.98 for inflammatory disease. IA1 strains carry higher frequencies of CAMP factors (CAMP1–4) driving IL-8-mediated neutrophil recruitment, NLRP3 inflammasome activation with IL-1β release, and keratinocyte apoptosis. IA1 forms biofilm within the sebaceous follicle – a structural community that resists both host immune clearance and antibiotic penetration, which is why antibiotic monotherapy reliably produces relapse the moment treatment pressure is removed. The bacteria were not cleared. They were sheltering. ^[2]

Phylotype IB and C. acnes subsp. defendens (commensal-associated): IB strains show an odds ratio of 0.5 for invasive infection. C. acnes subsp. defendens, characterised in a 2024 Frontiers in Microbiomes study, demonstrated confirmed anti-inflammatory properties in a rosacea-like mouse model – reducing IL-6, IL-1β, and erythema compared with IA1 challenge. In the healthy follicular microbiome, diverse C. acnes phylotype coexistence is itself anti-inflammatory: laboratory models show IA1 culture supernatant drives significant IL-6, IL-8, IL-10, and IL-17 upregulation; metabolites from IB and Type II strains suppress those markers when added. ^[9]

Extracellular vesicles. The IA1 threat extends beyond whole bacteria. C. acnes releases extracellular vesicles (EVs) – nanoscale membrane-bound packages of bacterial signalling molecules – that act on keratinocytes and sebocytes independent of intact bacterial cells. A 2024 comparative proteomic study established that EVs from acne lesions have a distinct protein profile from EVs of healthy-skin C. acnes populations: acne-site EVs are enriched in proteins driving Th1/Th17 inflammation and keratinocyte hyperproliferation. IA1-derived EVs drive sebocyte inflammation and comedogenesis through pathways that target whole-bacteria treatments address incompletely. ^[17]

The clinical translation is direct: treatments targeting whole C. acnes cells may leave an active inflammatory EV signal intact. This is the mechanistic explanation for why some patients maintain inflammatory lesions despite microbiological clearing – not treatment failure, but incomplete targeting. Approaches that operate at the inflammatory signalling level ( polynucleotides, CAP) rather than purely at the bactericidal level address this EV component as a secondary consequence of resolving the downstream inflammation the EVs are driving.

The sebum lipidome – a precision-target view

Sebum in acne-affected skin is not merely excessive. It is qualitatively different. Metabolomic profiling of acne sebum identifies distinct compositional signatures that may correspond to different acne subtypes and different optimal treatment approaches – an emerging precision medicine angle the field is beginning to formalise. ^[16]

Three overlapping sebum signatures emerge from the lipidomics literature:

Squalene peroxidation. Squalene – a precursor to cholesterol in the sebaceous lipid pathway – oxidises readily under UV radiation and pollution-derived free radical exposure. Squalene peroxides are potently pro-comedogenic, directly inducing follicular hyperkeratinisation and inflammatory cytokine release. This mechanism connects the exposome (UV, PM2.5) to comedogenesis at the sebum chemistry level, independently of the mTORC1 pathway.

Linoleic acid deficiency. Sebum in acne patients shows consistently reduced linoleic acid concentration – not from reduced dietary intake, but from dilution: excess triglyceride-rich sebum production reduces the proportional concentration of linoleic acid in the follicular content. Since linoleic acid is the omega-6 fatty acid essential for acylceramide formation in the follicular wall lining, its dilution impairs the barrier integrity of the follicular infundibulum, contributing to follicular hyperkeratinisation through the same lipid-deficiency mechanism that drives stratum corneum barrier dysfunction. ^{[14] [6]}

The clinical question – whether topical linoleic acid corrects this deficiency – is worth stating honestly. The mechanistic rationale is sound. The clinical evidence is limited to one randomised crossover trial (Letawe et al. 1998) showing approximately 25% reduction in microcomedo size over one month with topical linoleic acid versus no change at placebo sites, in mild comedonal acne. There is no RCT evidence for inflammatory lesion reduction. The correct position is that topical linoleic acid has plausible comedolytic potential in mild comedonal presentations through follicular barrier repletion – but it is a modest adjunct, not a standalone treatment, and should not be positioned as such. Linoleic acid-containing barrier formulations are most appropriately positioned as microenvironmental support alongside established retinoid-led topical therapy. ^[10]

Pro-inflammatory lipid mediators. Elevated leukotrienes (LTB4) and prostaglandins (PGE2) in acne sebum amplify NLRP3 inflammasome activity and sustain the neutrophil recruitment cycle. Omega-3 fatty acids (EPA/DHA) shift the eicosanoid balance away from pro-inflammatory LTB4 toward anti-inflammatory LTB5 – a mechanism complementary to, but distinct from, their PPARα activation pathway in keratinocytes.

The sebum metabolomics perspective on precision treatment suggests three broadly distinct acne phenotypes that may respond to different primary interventions: insulin-resistance-associated (prioritise mTORC1/androgen receptor targeting – isotretinoin, spironolactone, dietary modification); androgen-driven with normal metabolic profile (prioritise androgen receptor blockade – spironolactone, clascoterone); and oxidative/sebum-quality dominant (prioritise antioxidant strategies addressing squalene peroxidation and linoleic acid repletion alongside standard topical therapy). These categories overlap considerably, but the framing supports the clinical observation that two patients with clinically similar acne severity can respond very differently to the same first-line protocol.

The gut-skin axis – systemic amplification

The gut-skin axis in acne now has a degree of causal support that moves it beyond the “interesting association” category. Mendelian randomisation analyses have identified causal relationships between specific gut microbiota compositions and acne susceptibility – a methodological approach that controls for confounding better than standard observational correlation.

The proposed mechanism runs in parallel to the local follicular pathway: gut dysbiosis → increased intestinal permeability → systemic lipopolysaccharide (LPS) translocation → TLR4 activation → systemic elevation of IL-6 and TNF-α – amplifying the local follicular inflammatory environment through systemic immune priming. A dysbiotic gut is essentially providing a sustained pro-inflammatory background that makes the local follicular inflammatory response more severe than the local dysbiosis alone would produce. ^[18]

The evidence tier for probiotic intervention in acne is emerging. Lactobacillus acidophilus, L. rhamnosus GG, and combined probiotic formulations have shown reductions in inflammatory lesion counts in small clinical studies – likely through LPS translocation reduction, IL-10 upregulation, and systemic inflammatory tone reduction rather than any direct action on the pilosebaceous unit. This is not a replacement for topical retinoid therapy. But for clients with significant gut health disruption – IBS, history of multiple antibiotic courses, or gut-microbiome-perturbing dietary patterns – addressing the systemic amplification route alongside local treatment is mechanistically coherent. ^[15]

Antibiotic resistance – the honest picture

This deserves direct treatment rather than diplomatic qualification.

Erythromycin resistance in C. acnes has risen substantially – pooled resistance reached 29.20% (95% CI: 22.14–37.43%) in a 2025 global systematic review, a significant increase from approximately 10% in 2008. Macrolide resistance broadly is elevated, with clarithromycin at 77% in some regions. Doxycycline remains the most resistance-stable systemic antibiotic at approximately 2.44% resistance. ^[19]

The consequence is that macrolide-based antibiotic courses – among the most commonly prescribed for acne in UK primary care – are now ineffective in approximately a third of clinical presentations, generating selection pressure for further resistance whilst simultaneously eliminating the commensal C. acnes populations providing PPARα signalling, acid mantle acidification, RoxP antioxidant protection, and S. aureus competitive suppression. Antibiotic monotherapy, without concurrent BPO to prevent resistance development, is explicitly not recommended in current guidelines. Combination with BPO is not optional. ^[19]

Isotretinoin avoids resistance entirely: it operates through RAR/RXR receptor activation to suppress sebaceous gland activity and reduce the lipid substrate that C. acnes depends on – habitat removal, not antimicrobial killing – whilst simultaneously suppressing mTORC1 to address the upstream metabolic driver. Resistance to habitat removal is not a biological option.

Future directions – precision microbiome medicine

The therapeutic implications of the dysbiosis framing are beginning to produce genuinely novel approaches. Phage therapy – bacteriophage viruses selected to target specific C. acnes phylotypes – offers, in principle, the first intervention actually designed to achieve phylotype rebalancing: eliminating IA1 whilst leaving IB and Type II commensal strains intact. A 2023 Nature Communications mouse model study demonstrated that topical phage therapy effectively reduced inflammatory C. acnes burden while preserving microbiome diversity. Phage development programmes targeting C. acnes phylotype-specific reduction are in pre-clinical development, with several programmes under investigation as of 2025. ^[13]

AI-designed antimicrobial peptides against C. acnes IA1 represent a parallel precision approach: a 2024 study identified five of 42 AI-generated candidates with minimum inhibitory concentrations of 2–4 µg/mL – comparable to established topical antimicrobials. ^[5] Neither approach is close to standard clinical use. But both are conceptually significant: they are the first treatment strategies aligned with the correct disease model, targeting the phylotype shift rather than using broad-spectrum elimination as an imprecise proxy for it.